Author
Icahn School of Medicine at Mount SinaiORCID 0000-0002-0492-9904Unclaimed ORCID profile · follow to get notified of new preprints
Mutual co-authors in cluster
6 papers
Recent·Most cited
Virgil L. Woods, Tyler J. Umansky, Sean M. Russell…·Daniel J. Haders
This paper evaluates MDL-001, a broad-spectrum antiviral, showing potent in vitro and in vivo activity against influenza, RSV, SARS-CoV-2, and hepatitis B/C/D viruses, with improved efficacy compared to existing treatments.
N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva…·Arnab K. Chatterjee
This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.
Van Ngoc Thuy La, Noa Lahav, Moshe Goldsmith…·David D. L. Minh
The paper compares three data analysis methods for MERS-CoV MPro inhibitors, finding that modeling the complete concentration-response curve best predicts cellular efficacy.
Ed Griffen, D. Fearon, Briana Lynn McGovern…·Annette von Delft
This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.
Alpha A. Lee, Isabelle Amick, Jasmin Cara Aschenbrenner…·Max Winokan
The paper identifies potent nsp3-mac1 inhibitors but finds they do not translate to antiviral activity in cell culture models.
Mehdi Bouhaddou, Ann‐Kathrin Reuschl, Benjamin J. Polacco…·Nevan J. Krogan
The paper systematically analyzes proteomic and genomic data of SARS-CoV-2 variants to identify how mutations affect viral gene expression, host interactions, and immune evasion.